
About Therapure Biopharma
Therapure Biopharma is a Healthcare company based in Mississauga (Canada) founded in 2008. Complex biologics are developed and manufactured by Therapure Biopharma. Therapure Biopharma offers products and services including Biomanufacturing Services and Drug Innovations. Its focus areas include Diversified Pharmaceuticals, Biopharma Outsourcing, CDMO and Biologics. Its legal entity is Therapure Biopharma Inc.
Company details
Therapure Biopharma focuses on manufacturing complex biologics and on developing, manufacturing, and selling its blood and plasma-related therapeutic products. It operates through three divisions: Therapure Biomanufacturing (Mammalian cell line based CDMO), Therapure Biologics (Plasma-derived products), and Therapure Innovations (Proprietary drug development). It provides contract development and manufacturing services for integrated biologics and also offers drug discovery, research, and development services. The company also focuses on the development of a portfolio of its own plasma-derived protein therapeutics through its technology, PlasmaCap EBA (for efficient capture of plasma proteins at high yields and purities). Therapure Innovations lead candidates TBI 302 (liver cancer) and TBI 304H (anemia) are undergoing phase I trials while TBI 301 (Hep C) is in the discovery stage. The company is funded by the Catalyst Capital Group since its inception. The companys CDMO business and certain rights to their plasma products and technology for the Chinese market were acquired by a JV between 3SBio and CPE funds.
- Headquarters Mississauga, Canada
- SectorsHealthcare
- Website therapurebio.com
- Social LinkedIn X
- Legal Name Therapure Biopharma Inc.
- Latest Funding Round$20M (USD), Debt – Conventional
Aug 2015
- InvestorsOntario Canada
& 1 more
Products & Services of Therapure Biopharma
Therapure Biopharma offers a comprehensive portfolio of products and services, including Biomanufacturing Services and Drug Innovations.
Offers integrated biologics CDMO for efficient production and development.
Develops protein therapeutics for diseases like liver cancer and anemia.
Funding Insights of Therapure Biopharma
- Total Rounds 2
- Last Round Debt – Conventional — $20M
- First Round $4.2M
(Apr 2010)
- Investors Count 2
All 2 funding rounds of Therapure Biopharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2015 | $20M | Debt – Conventional | – | – | |
| Apr 2010 | $4.2M | Grant | – | – |
2 investors in total: 2 institutional.
Investors in Therapure Biopharma
Therapure Biopharma has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Ontario Canada and FedDev Ontario.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
It serves as a government backed investment fund focused on the economic growth of southern ontorio. | 2009 | feddevontario.gc.ca | Waterloo, Canada | |
Access government services and products | 1881 | ontario.ca | Toronto, Canada |
Investor details for Therapure Biopharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Therapure Biopharma
3 dated milestones of Therapure Biopharma across 7 years, from founding to its latest funding, stage changes and deals.
- Founded Therapure Biopharma is founded.
- Funding First funding round of $4.2M.
- Funding Latest funding round, Debt – Conventional, of $20.0M.
Web traffic of Therapure Biopharma
Websites that share an audience with Therapure Biopharma (therapurebio.com).
Websites whose visitors overlap most with Therapure Biopharma. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| corerxpharma.com | 100% | View details | |||
| contractpharma.com | 99% | 67.7K | #631,663 | View details | |
| pharmatek.com | 99% | View details | |||
| dptlabs.com | 98% | 1.5K | #8,022,749 | View details | |
| nutritionallabs.com | 61% | View details |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Therapure Biopharma
Complete news archive for Therapure Biopharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Therapure Biopharma
Therapure Biopharma was founded in 2008 and raised its 1st funding round 2 years after it was founded.
Therapure Biopharma is headquartered in Mississauga, Canada. It is registered at Mississauga, Ontario, Canada.
Therapure Biopharma focuses on manufacturing complex biologics and on developing, manufacturing, and selling its blood and plasma-related therapeutic products. It operates through three divisions: Therapure Biomanufacturing (Mammalian cell line based CDMO), Therapure Biologics (Plasma-derived products), and Therapure Innovations (Proprietary drug development). It provides contract development and manufacturing services for integrated biologics and also offers drug discovery, research, and development services. The company also focuses on the development of a portfolio of its own plasma-derived protein therapeutics through its technology, PlasmaCap EBA (for efficient capture of plasma proteins at high yields and purities). Therapure Innovations lead candidates TBI 302 (liver cancer) and TBI 304H (anemia) are undergoing phase I trials while TBI 301 (Hep C) is in the discovery stage. The company is funded by the Catalyst Capital Group since its inception. The companys CDMO business and certain rights to their plasma products and technology for the Chinese market were acquired by a JV between 3SBio and CPE funds.
Therapure Biopharma offers Biomanufacturing Services and Drug Innovations.
Therapure Biopharma has 2 investors. Key investors include Ontario Canada, and FedDev Ontario.
Therapure Biopharma operates through Therapure Biopharma Inc..
